StockData
Atossa Therapeutics, Inc. logo

Atossa Therapeutics, Inc. (ATOS) stock

ATOSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.90−0.03 (-1.55%)

Close on Nov 17, 2026Market cap $18.96MP/E –Yield –

Atossa Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Atossa Therapeutics's price to sales ratio was 339.6× on Jan 30, 2015, against 63.0× a year earlier. Over the last 2 years it ranged from 36.1× to 415.0×, with a median of 120.9×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2015Jan 30, 2015339.6×−75.5
2014Dec 31, 2014415.0×+355.8
2013Dec 31, 201359.2×−63.6
2012Dec 31, 2012122.8×–

More Atossa Therapeutics figures

See a number that looks wrong?